anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The adolescence period is the transition from childhood to adulthood. Adolescents are vulnerable to many biomedical exposures, such as a low-quality diet, fewer fruits and vegetable intake, low physical activities, smoking habits, and alcohol consumption; and non-biomedical aspects such as mental depression, parental distress, and household income, which were known to be associated with increased risk of many health outcomes. Obese adolescents are vulnerable to many infections, poor disease outcomes and complications, and lower antibody response to vaccinations. Studies that have investigated Covid-19 incidence in overweight and obese individuals are still scarce. Adolescence is also a sensitive period to microbial change or dysbiosis due to practicing poor diet, low physical activity, inadequate sleep, stress, and substance use (smoking, drugs, and alcohol). Despite the existing prevalence of SARS-COV-2 infections is increasing in adolescents, and the vaccine program is not prioritized in this population, making the prevention strategy for SARS-COV-2 infection may become less effective in this population. Besides, low-quality diet and lifestyle habits and family cluster transmission at home are often not fully addressed in the policy. These factors may be the contributors to the potential highest COVID-19 exposure for children and adolescents. Since exposure among adolescents is linked to serious adverse health effects, effective interventions to improve nutritional outcomes and reduce the risk of COVID-19 infection will provide substantial long-term returns. However, such interventions for adolescents in Indonesia and globally are lacking.

This study is a randomized clinical trial (RCT) and placebo parallel controlled study. The research will be conducted in junior and senior high schools in Jakarta, Surabaya, and Yogyakarta, Indonesia.

In light of COVID-19 outbreak, if face-to-face activities are permitted by (1) national government (Indonesian Ministry of Health), (2) local government (DKI Jakarta), (3) the university, (4) Data Safety Monitoring Board, and (5) by consent of the subject, then the activities need to be strictly adjusted with the COVID-19 prevention measures for both personnel and subjects. All personnel and subjects who will be involved in the activities are required to fill out the COVID-19 symptom screening form prior to the visit and have been vaccinated with a complete dose.
Topical administration of a generator of H 2 S in biological tissues for the treatment of eye disorders, such as glaucoma. NaHS caused a time-dependent decrease in intrancular pressure in nomotensive, conscious albino rabbits indicating a similar role for H 2 S in the regulation of aqueous humor dynamics in animals and humans. H 2 S donors, NaHS and Na2S, inhibited field-stimulated [3H]NE release from porcine isolated iris-ciliary bodies and produced relaxation of pre-contracted iris muscle strips indicating a pharmacological role for H 2 S in the anterior uvea. The observation that donors of H 2 S can alter sympathetic neurotransmission and induce an inhibitory action on iris smooth muscle suggests that this gas has the potential to influence several physiological/pathological processes in the eye. The ability of NaHS or Na2S to inhibit [3H]NE release mimics the well-established action some antiglaucoma drugs (e.g. α2-adrenoceptor agonists, prostaglandins) on sympathetic neurotransmission in the anterior uvea and can be used to reduce IOP in animals and humans.
The invention discloses a traditional Chinese medicine composition for treating malignant lymphoma. The composition comprises Angelica, Ligusticum wallichii, radix paeoniae rubra, rehmanniae radix, Radix Scrophulariae, edible tulip, airpotato yam, seaweed, kelp, prunella vulgaris, oyster, Paris polyphylla, trigone, rhizoma curcumae, Rhizoma Cyperi, scorpion, centipede, semen brassicae, pericarpium citri reticulatae viride, Fructus aurantii and Radix bupleuri. The invention uses methods of reducing phlegm and resolving masses, and regulating qi and dissipating stasis. Aiming at the etiology and pathogenesis of malignant lymphoma, the invention provides a novel treatment concept: occurrence, development and ending of malignant lymphoma lay in qi. Qi stagnation causes blood stasis, and blood stasis causes phlegm accumulation, and phlegm accumulation causes abdominal masses, which lead to tumor. Accordingly, the invention adopts a group of traditional Chinese medicines which can permeate qifen. Rectifying qi can smooth the liver, and guiding qi downward can realize smoothness, and relieving stagnant qi can dissipate stasis. Ancient medicine believes in invigorating the spleen to eradicate source of phlegm, and today the invention utilizes pectoral qi to eliminate the foundation of tumor, so as to treat lymphatic cancer from the foundation; and coupled with medicines for dissipating phlegm, the lymphatic cancer can be cured. All parties are played together to smooth the liver, rectify qi, draw out poison, relieve swelling, break masses, dissipate stasis, benefit water-dampness, relieve phlegm coagulation, reduce cancer, strengthen the body resistance to eliminate pathogenic factors and resist cancer.
There are many methods to treat keloid, including various excision operations, laser, injection and radiotherapy. However, few studies have explored the effectiveness of single-hole punch excision in keloid treatment. This study aimed to investigate the efficacy and safety of lateral punch excision combined with intralesional steroid injection for keloid treatment through self-control trial. In this self-controlled trial, 50 patients meet the diagnosis of nodular keloid, and try to choose left-right symmetrical control, one skin lesion in the control group (50 skin lesionsin total) and the other in the observation group (50 skin lesions in total).The keloids in the treatment group were initially treated with punch excision combined with intralesional steroid injection, followed by injection treatment alone. Keloids in the control group received intralesional steroid injection alone. The Vancouver Scar Scale (VSS) of the keloid before and after the punch excision was evaluated; the keloid scores at different time points and the number of injection treatments required in both groups were compared, and adverse reactions were observed. The effective rate of the observation group was 86.0%, which was significantly higher than that of the control group (66.0%), and the recurrence rate of 22% was lower than that of the control group (χ2 = 4.141,63417), all of which were statistically significant (all P < 0.05). At the end of treatment, the VSS and total injection times in the observation group were significantly lower than those in the control group (t = 5.900,3.361), with statistical significance (P < 0.01). The combination of single-hole punch excision and intralesional steroid injection is an effective method to treat multiple nodular keloids, shortening the treatment course of tralesional steroid injection without obvious adverse reactions.
This is a phase II, open-label trial to evaluate valganciclovir as a treatment to prevent development of sensorineural hearing loss (SNHL) in infants with asymptomatic congenital cytomegalovirus (CMV) infection. The trial will be conducted in two phases - screening of newborns to identify eligible subjects, and treatment of those newborns who have confirmed CMV infection at birth but without outward manifestations of congenital CMV infection. Approximately 48,250 newborn infants with no outward manifestations of congenital CMV infection will be screened to detect approximately 241 neonates with asymptomatic congenital CMV infection; these 241 newborns then will have audiology examinations to determine baseline hearing, with approximately 229 having normal hearing in both ears. Those 229 newborns with confirmed CMV infection but without baseline SNHL and who meet all inclusion/exclusion criteria will be enrolled into the treatment phase. Enrolled subjects will be treated for four months with oral valganciclovir (16 mg/kg/dose, administered two times per day). Audiologic assessments will be made during the Screening Period and Study Months 4 (end of treatment), 6, 12, and 18. Treated infants will be followed for safety throughout the first 6 months of the study (including for 2 months post-treatment). Study duration is 5 years. Primary objective of this study is to estimate the proportion of subjects with asymptomatic congenital CMV infection who, following treatment with 4 months of oral valganciclovir, develop sensorineural hearing loss (SNHL) by 6 months of life. Secondary objectives are to: 1) define the safety and tolerability of valganciclovir in enrolled subjects, 2) estimate the proportion of subjects with asymptomatic congenital CMV infection who, following treatment with 4 months of oral valganciclovir, develop SNHL over the first 18 months of life.
"Financial toxicity" refers to a side effect of cancer treatment that is financial in nature, and has become increasingly important to oncologists, patients, and researchers because of its implications in adverse social outcomes for patients. Financial toxicity in the context of cancer care is the monetary cost, and subsequent social implications of the cost, on patients undergoing cancer treatment. Although financial toxicity for patients undergoing cancer treatment has some research attention, financial toxicity associated with radiation therapy for cancer patients has not. There is preliminary data that has shown that there are two forms of financial toxicity: the direct cost of cancer therapy (medical services) and the indirect costs (gas for travel, lost wages for sick days, etc.). However, the degree of cost and sources have not been fully investigated. Specifically, financial toxicity in the context of cancer patients from rural populations (such as those at NCCC) has not been fully explored. This project will attempt to understand the salient factors, costs, and magnitudes of financial toxicity in radiation therapy that will allow for more targeted studies to investigate vulnerable patient populations who experience greater financial toxicity.

Study recruitment temporarily halted due to COVID-19.
Patients will be asked by a member of the research team if they would like to participate in this study evaluating patients' comprehension of the informed consent for the oncology treatment study that they are participating in. Patients will be consented and will be told that, at their next clinical visit, they will be given the questionnaire to complete. They will be given the option to complete the questionnaire on site after being given the document or have the ability to mail the completed questionnaire into the research office once completed. If the questionnaire is not returned within 2-weeks, the participant will be approached again during their normal clinical visit and asked if they still wish to participate in this study.
PURPOSE:To provide the titled plaster capable of keeping the drug stably without causing decomposition, by adding a riboflavin compound to a plaster composed of an adhesive substance. CONSTITUTION:A plaster composed of an adhesive substance such as a diene polymer, a (meth)acrylic ester copolymer. etc. and optionally a tackifier, an agent for regulating the adhesive and holding power, a filler, etc., is compounded with riboflavin, its derivative (e.g. riboflavin phosphoric acid ester) or their salt. The amount of the riboflavin, etc. is 0.005-10wt%, preferably 0.05-5wt%, based on the whole plaster. When a drug applicable to skin is compounded to the plaster, an adhesive drug preparation having stable drug content with time can be obtained. The composition is especially effective when the drug is a compound containing phenolic OH group or an amino compound.
BACKGROUNDS: Radical resection is the most effective treatment for perihilar tumors. Biliary tract reconstruction after resection is one of the key steps in this surgery. Mucosa-to-mucosa cholangiojejunostomy is traditionally performed, in which the bile ducts at the resection margin are separately anastomosed to the jejunum. However, this approach is associated with long operative time and high risk of postoperative complications. The present study presents a modified technique of hepatojejunostomy and its outcomes.
METHODS: The data of patients who underwent hepatojejunostomy using the modified technique at the Department of Hepatobiliary Surgery, Daping Hospital, Army Medical University, Chongqing, China, from January 2016 to December 2021, were retrospectively analyzed.
RESULTS: A total of 13 patients with perihilar tumors underwent R0 resection and bilioenteric reconstruction using the modified hepatojejunostomy technique during the study period. During the operation, the alignment of the bile duct stumps was improved, the posterior wall of the anastomosis was reinforced, internal stents were placed in the smaller bile ducts, external stents were placed in the larger bile ducts, and hepatojejunostomy was performed using 4 - 0 prolene. No serious postoperative complications, such as death or bile leakage, occurred during the hospitalization. Furthermore, there were no cases of biliary stricture or cholangitis after the six-month follow-up period.
CONCLUSION: The modified hepatojejunostomy technique is a safe and effective technique of biliary reconstruction after the resection of perihilar tumors. This can be easily performed for difficult cases with multiple bile ducts that require reconstruction after resection.
PURPOSE: To provide a powder colored cosmetic compsn. having improved aesthetic characteristic and performance characteristics. CONSTITUTION: This powder colored cosmetic compsn. contains i) talc of an average grain size of 2 to 8 μm existing in the amt. effective for curing cosmetics and ii) mica of an average grain size of 2 to 8 μm existing in the amt. effective for embrittlement of the cosmetics.
Each participant will be treated with topical ivermectin cream 0.5% qd for one half of the face for 1 month. In the second month all patients will be treated with ivermectin cream for the entire skin involvement.
PURPOSE:The titled bath agent, obtained by incorporating hot spring inorganic components in a weakly acidic bath agent prepared by impregnating other components with gaseous carbon dioxide or containing a carbonate and an acid and capable of further enhancing the bathing effect due to vasodilator action of the gaseous carbon dioxide, etc. CONSTITUTION:A weakly acidic bath agent obtained by incorporating (A) hot spring inorganic components, e.g. spray-dried material from hot water of KUSATSU ONSEN, and, as necessary, (C) a crude drug, e.g. Japanese angelica root, together in (A) a weakly acidic bath agent prepared by impregnating other components with gaseous carbon dioxide or containing a carbonate and an acid, preferably at 5-80wt% carbonate and 10-80wt% acid and capable of exhibiting 4-7, particularly 6.0-6.7pH of a 0.01wt% aqueous solution thereof, and capable of remarkably improving the blood circulation promoting effect and effect on keeping of the body warm, etc., of the above-mentioned bath agent by the synergistic effect of the components (A)-(C). The above-mentioned bath agent gives a good influence on the skin due to the weak acidity thereof and exhibits improved blood circulation promoting effect due to the gaseous carbon dioxide present as CO2 molecules. The amounts of the components (B) and (C) based on the total composition are preferably as follows: 0.5-10wt% component (B) and 0.001-10wt% component (C).
Abnormal tissue or malignant organelles within such tissue are destroyed by alpha particles emitted by radionuclide cores that are linked to the abnormal tissue. Targeted radionuclide beads each includes an alpha emitter radionuclide core (12) to which a plurality of antibody linking sites (14) are coupled. Surrounding the linking sites and radionuclide core is a polymeric shell (16) that absorbs alpha particles emitted by the core. A reagent (18) is applied to or included within the polymeric shell. Depending upon the material used for the reagent, it is activated by light of a particular waveband that is selectively applied after antibody linking sites (20) on the exterior of the shell have linked the targeted radionuclide to abnormal tissue in the body of a patient. Certain reagents are activated by light in a waveband corresponding to an absorption waveband of the reagent, while other types of reagents are activated by ultrasonic energy applied from an ultrasound source. When thus activated, the reagent causes fragmentation of the polymeric shell, enabling the alpha particles to pass into the abnormal tissue to which the radionuclide core becomes linked. The alpha particles destroy the abnormal tissue. It is also contemplated that the radionuclide core may instead emit beta particles, which though less toxic than alpha particles, can still destroy the targeted abnormal tissue.
PROBLEM TO BE SOLVED: To obtain the subject excellent treating agent containing a specific carbostyril derivative as an active ingredient, especially useful as a treating agent for schizophrenia and free from serious adverse effects, e.g. motility disturbance such as akathisia. SOLUTION: This treating agent contains a carbostyril derivative of the formula (R is a lower alkyl; a bond between carbons at 3 position or 4 position of carbostyril skeleton represents single bond or double bond) or its salt as an active ingredient. As the compound of the formula or its salt, 5-(2-hydroxy-3- tert-butylamino)-propoxy-3,4-dihydroxycarbostyril hydrochloride is preferably used. When the compound of the formula or its salt is used alone, the treating agent is administered so that the daily effective ingredient amount in the treating agent may be 15-30mg/adult. The treating agent is preferably administered once or three times daily. Further, effective ingredient amount in the treating agent is preferably normally 0.1-2wt.%. Furthermore, the treating agent is preferably combinedly used with anti-schizophrenic medicine such as chlorpromazine hydrochloride.
PURPOSE: Our goal is to understand how the different types of plural marking are understood and processed by children with cochlear implants (CIs): (a) how does salience affect the processing of plural marking, (b) how is this processing affected by the incomplete signal provided by the CIs, and (c) is it linked to individual factors such as chronological age, vocabulary development, and phonological working memory?
METHOD: Sixteen children with CIs and 30 age-matched children with normal hearing (NH) participated in an eye-tracking study. Their task was to choose the corresponding picture to an auditorily presented singular or plural noun. Accuracy, reaction time, and gaze fixation were measured and analyzed with mixed-effect models.
RESULTS: Group differences were found in accuracy but not in reaction time or gaze fixation. Plural processing is qualitatively similar in children with CIs and children with NH, with more difficulties in processing plurals involving stem-vowel changes and less with those involving suffixes. Age effects indicate that processing abilities still evolve between 5 and 11 years, and processing is further linked to lexical development.
CONCLUSIONS: Our results indicate that early implantation seems to be beneficial for the acquisition of plural as indicated by very small between-group differences in processing and comprehension. Processing is furthermore affected by the type of material (i.e., phonetic, phonological, or morphological) used to mark plural and less so by their segmental salience. Our study emphasizes the need to take into account the form of the linguistic material in future investigations at higher levels of processing.
Patients receive standard of care lymphodepletion therapy consisting of cyclophosphamide and fludarabine on days -5 to -3 followed by liso-cel CAR-T cell infusion on day 0. Patients then receive NKTR-255 IV over 30 minutes every 3 weeks starting on day 10 or 14 for up to 3 doses in the absence of disease progression or unacceptable toxicity. Patients undergo chest x-ray and ECHO or MUGA during screening. Patients undergo bone marrow biopsy and aspiration, LP for CSF sample collection during screening, on the study and during follow-up as clinically indicated. Patients also undergo PET/CT throughout the trial. Additionally, patients undergo blood sample collection and may optionally undergo tissue biopsy throughout the trial.
PURPOSE:To obtain a skin drug for external use, capable of exhibiting synergistic effects on inhibitory action on erythema by ultraviolet rays and curing action on wounds, by using allantoin or a derivative thereof and kojic acid or an ester thereof together. CONSTITUTION:A skin drug for external use, obtained by blending (A) one or more of allantoin or derivatives thereof, e.g. dihydroxyaluminum allantoinate or chlorohydroxyaluminum allantoinate, with (B) one or more of kojic acid or esters thereof expressed by the formula (R<1> and R<2> are H or 3-20C acyl) as essential ingredients in a skin drug for external use, such as cosmetic, e.g. cream, toilet water, pack or powder, or medicine or quasi drug, e.g. emulsion, lotion, liniment agent or ointment, and having the above-mentioned effects. The amounts of the blended ingredients are normally 0.01-5.0wt.%, preferably 0.05-2.0wt.% ingredient (A) and normally 0.01-20wt.%, preferably 0.1-2wt.% ingredient (B).
Single IV dose of placebo will be administered via IV over approximately 1 hour on Day 1. No other doses will be administered during the study.
The invention discloses a theaflavin health-care food or medicament and a preparation method of the theaflavin health-care food or medicament. The theaflavin health-care food or medicament is prepared from the following components: tea extract based on theaflavin and tea seed oil in a weight ratio of (1:2)-(1:5), a suspending aid in an amount which is 1 to 8 percent of the total weight of the tea seed oil, and a wetting agent in an amount which is 0.5 to 8 percent of the total weight of the tea seed oil. The preparation method comprises the following steps of: adding the suspending aid into the tea seed oil according to the weight ratio, heating for melting, cooling to room temperature, adding the tea extract and the wetting agent, grinding uniformly in a colloid grinder to obtain capsule liquid, performing post treatment, and thus obtaining the theaflavin health-care food or medicament in a formulation of soft capsules. The theaflavin health-care food or medicament has the effects of resisting oxidation, reducing blood fat, improving the immunity, resisting tumors and the like. The prepared soft capsules can be prevented from being in contact with air, enhances the stability, and can improve the bioavailability. The preparation method for the theaflavin soft capsules is simple, easy to implement and extremely high in production efficiency.
The invention relates to a traditional Chinese medicine for treating diabetes mellitus, the preparation method and application thereof. Current drugs for treating diabetes mellitus are mainly drugs of decreasing glucose and insulin injection drugs. These can only control the symptoms temporarily, with strong dependence and continuous administration and the disease cannot be removed and cured, i.e. the current drugs cannot cure islet cell functional defect in that only short-term symptoms can be relieved and the curative effect is not ideal and relapse occurs after discontinuation. Therefore, a drug used for treating diabetes mellitus is needed in the market. The traditional Chinese medicine is humulus. The invention is used for treating a variety of diabetes mellitus.
Extended quit and win contests (3 successive monthly contests) plus motivational and problem-solving counseling (MAPS). {Smoking abstinence, 3 contest prize awards (contests 1, 2 and 3) plus Counseling phone calls.